Breaking Finance News

Piper Jaffray upgraded Inovio Pharmaceuticals INO (NYSE:INO) from Neutral to Overweight in a report released today.

Piper Jaffray has upgraded Inovio Pharmaceuticals INO (NYSE:INO) from Neutral to Overweight in a report released on 6/08/2017.

Previously on 5/26/2017, Aegis reported about Inovio Pharmaceuticals INO (NYSE:INO) raised the target price from $11.00 to $14.00. At the time, this indicated a possible upside of 0.78%.

Yesterday Inovio Pharmaceuticals INO (NYSE:INO) traded -2.33% lower at $8.15. The company’s 50-day moving average is $6.13 and its 200-day moving average is $6.65. The last stock close price is up -5.40% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 1,212,718 shares of the stock were exchanged, down from an average trading volume of 1,593,870

See Chart Below

Inovio Pharmaceuticals INO (NYSE:INO)

Inovio Pharmaceuticals INO has a 52 week low of $5.28 and a 52 week high of $9.86 The company’s market cap is currently $0.

In addition to Piper Jaffray reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is $18.60 with 2 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Inovio Pharmaceuticals INO (NYSE:INO)

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.